Big Jump in PFS With Combo for Indolent NHL
(MedPage Today) -- Lenalidomide-rituximab more than doubles PFS in relapsed/refractory disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 26, 2019 Category: Hematology Source Type: news
U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid. (Source: Reuters: Health)
Source: Reuters: Health - March 14, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Drug Combo Granted Priority Review for Untreated Follicular Lymphoma
The FDA has granted Priority Review to Celgene ’s application for lenalidomide in combination with rituximab for previously untreated follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - March 12, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
Lenalidomide Maintenance vs Observation For Newly Diagnosed Myeloma
Can lenalidomide maintenance significantly improve progression-free survival in patients with newly diagnosed myeloma? (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
MRD Status a Superior Predictor of PFS in Multiple Myeloma?
The study also looked at how lenalidomide maintenance further increases the rate of negative MRD results in multiple myeloma patients. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
Lenalidomide cost effective in newly diagnosed multiple myeloma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2019 Category: Drugs & Pharmacology Source Type: news
Addressing uncertainty in cost-effectiveness case for lenalidomide
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2019 Category: Drugs & Pharmacology Source Type: news
ASH Poster Rounds: Adding BTK Inhibitor Safe in First-Line MCL
(MedPage Today) -- Plus: Lenalidomide upfront in PTCL; skipping RT in primary mediastinal B-cell lymphoma (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 7, 2018 Category: Hematology Source Type: news
Daratumumab Plus Len/Dex: New Standard of Care in Myeloma? Daratumumab Plus Len/Dex: New Standard of Care in Myeloma?
Adding daratumumab to lenalidomide and dexamethasone increased progression-free survival in transplant-ineligible patients newly diagnosed with myeloma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 6, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Early Intervention With New Drug Combo Beneficial in Myeloma?
This study looked at the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news
Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma
WEDNESDAY, Nov. 7, 2018 -- For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival is longer in those receiving the immunostimulatory monoclonal antibody elotuzumab in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 7, 2018 Category: Pharmaceuticals Source Type: news
FDA OK's New Triplet Tx for Revlimid-Refractory Multiple Myeloma
(MedPage Today) -- Agent doubled overall response rate, progression-free survival (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 7, 2018 Category: American Health Source Type: news
Rituximab & #43; Lenalidomide Effective in Follicular Lymphoma
TUESDAY, Sept. 11, 2018 -- Rituximab plus lenalidomide has similar efficacy to rituximab plus chemotherapy among patients with previously untreated follicular lymphoma, according to a study published in the Sept. 6 issue of the New England Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 11, 2018 Category: Pharmaceuticals Source Type: news
Obinutuzumab/Lenalidomide Combo Safe, Effective in Advanced Follicular Lymphoma
The combination of obinutuzumab and lenalidomide was found to be effective in relapsed or refractory follicular B-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
